Press Release Corporate Communications

Total Page：16

File Type：pdf, Size：1020Kb

Matthias Link Press Release Corporate Communications Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Deutschland T +49 6172 608-2872 F +49 6172 608-2294 [email protected] www.fresenius.com September 1, 2015 Fresenius joins EURO STOXX 50 index Fresenius SE & Co KGaA will be included in the EURO STOXX 50 blue-chip index on September 21, 2015. The index update was announced by the Deutsche Börse subsidiary STOXX after the close of trading on Monday night. The EURO STOXX 50 index tracks the share price development of 50 large publicly traded companies, representing various economic sectors, from twelve Eurozone countries. Fresenius joined Germany’s blue-chip DAX index in March 2009, and has continued to post strong growth since then. Group sales almost doubled from €12.3 billion in 2008 to €23.2 billion in 2014. Over the same period, adjusted Group net income increased from €450 million to €1.086 billion. Fresenius, which has more than 220,000 employees worldwide, has ambitious growth targets for this year. Group sales for 2015 are expected to rise by 8% to 10% in constant currency, while adjusted Group net income is forecasted to increase by approximately 18% to 21% in constant currency. # # # Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2014, Group sales were €23.2 billion. On June 30, 2015, the Fresenius Group had 220,339 employees worldwide. For more information visit the Company’s website at www.fresenius.com. Follow us on Facebook and Twitter: www.facebook.com/fresenius.group and http://www.twitter.com/fresenius. Page 1/2 This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release. Fresenius SE & Co. KGaA Registered Office: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11852 Chairman of the Supervisory Board: Dr. Gerd Krick General Partner: Fresenius Management SE Registered Office: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Dr. Ulf M. Schneider (Chairman), Dr. Francesco De Meo, Dr. Jürgen Götz, Mats Henriksson, Rice Powell, Stephan Sturm, Dr. Ernst Wastler Chairman of the Supervisory Board: Dr. Gerd Krick Page 2/2 .

Copy Link

Recommended publications

Conversion Report (PDF, 958
This document is an English translation of the original German language document. The translation is exclusively for convenience purposes. Only the original German language document is authorative and binding. Fresenius SE Change of the Legal Form into a Partnership Limited by Shares Conversion Report of the Management Board Convenience Translation Important Notice: This conversion report is neither an offer to sell voting ordinary bearer shares or non-voting preference bearer shares, nor an invitation to make the Company an offer to buy voting ordinary bearer shares or non-voting preference bearer shares. Such an offer requires special publication as the case may be, and, in so far as required by national law, a separate prospectus. This conversion report is not an offer to sell securities in the United States of America (USA). Securities may be sold or offered for purchase in the USA only with prior registration or without prior registration only on the basis of an exception provided. This conversion report is neither an offer to sell voting ordinary limited partner shares nor an invitation to make the Company an offer to buy voting ordinary limited partner shares. Such an offer requires special publication as the case may be, and, in so far as required by national law, a separate prospectus. This conversion report is not an offer to sell securities in the USA. Securities may be sold or offered for purchase in the USA only with prior registration or without prior registration only on the basis of an exception provided. This document does not constitute an offer document or an offer of transferable securities to the public in the United Kingdom to which section 85 of the Financial Services and Markets Act 2000 of the United Kingdom (“FSMA”) applies and should not be considered as a recommen- dation that any person should subscribe for or purchase any securities as part of the Transaction.
[Show full text]
European Accounting and Management Review
EAMR EUROPEAN ACCOUNTING AND MANAGEMENT REVIEW VOLUME 5, ISSUE 1, ARTICLE 2, 21-46, NOVEMBER 2018 Value Creation and Women on Boards Bettina C.K. Binder Hochschule Pforzheim Received September 8, 2018; accepted October 26, 2018. ABSTRACT Value creation is a major claim of most companies. Mahajan (2017) argues that “value and value creation are natural to and basic in human behaviour and endeavour”, nevertheless women are often marginalized and impeded in their advancement towards leadership positions, where they could shape and influence the process of value creation. The present article looks at the companies of EURO STOXX 50 index in the year 2015 and offers an overview of women representation on the boards of these 50 companies. The paper tries to establish whether the success of these companies can be related to the percentage of female members in supervisory positions. The findings reveal the existence of a weak correlation between Earning before Taxes (EBT) and the proportion of women on the boards of the EURO STOXX 50 companies. KEYWORDS Value creation, women on supervisory boards, key performance indicators, gender quota, earnings before taxes. Bettina C.K. Binder 1. Introduction Value creation is a major claim of most companies and when leafing through the annual reports of companies one encounters expressions such as “value to our shareholders”, “we provide value for our customers”, “we create value for our employees, shareholders, business partners, neighbours and the public”, etc. While it seems to be clear for whom value is created, the concept of “value” itself is subjected to various interpretations and is regarded in the literature as ambiguous (Lepak, Smith and Taylor, 2007; Marinova, Larimo and Nummela, 2017).
[Show full text]
Market Data from Deutsche Börse
Market Data + Services Market data from Deutsche Börse Real-time. Reliable. Relevant. Deutsche Börse is a global German company Providing access to international capital markets Market data from Deutsche Börse 3 Deutsche Börse Group A global market operator Deutsche Börse Group, whose history dates back to 1585, is today one of the largest exchange organisations world-wide. The Group is headquartered in Germany and has more than 4,000 employees working to provide investors, financial institutions and companies access to global capital markets. Deutsche Börse Group’s integrated business model covers the entire process chain from securities and derivatives trading, clearing, settlement and custody, through to market data and the development and operation of electronic trading systems. Deutsche Börse Group owns the derivatives trading venue Eurex Exchange, as well as the settlement and custody business Clearstream. The Group’s market data business, operated by Market Data + Services, is trusted by more than 2,500 institutions and 160,000 subscribers. Deutsche Börse Group’s business areas Deutsche Börse Group Eurex Xetra Clearstream Market Data + Exchange Services Cash Settlement, market trading financing services Derivatives Information, indices, market trading tools, market solutions Simplified illustration Trademarks AlphaFlash ®, CEF ®, DAX ®, Eurex ® and Xetra ® are registered trademarks of Deutsche Börse AG. STOXX ® and EURO STOXX 50 ® are registered trademarks of STOXX Limited. Information is the basis for successful decision making
[Show full text]
Fresenius Achieves 2020 Targets and Expects Healthy Business Development in 2021 Despite Ongoing COVID-19 Impact
Markus Georgi Investor News Senior Vice President Investor Relations & Sustainability Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2485 F +49 6172 608-2488 [email protected] www.fresenius.com February 23, 2021 Fresenius achieves 2020 targets and expects healthy business development in 2021 despite ongoing COVID-19 impact • Preliminary guidance for 2021 confirmed • Strategic roadmap for accelerated growth through 2023 and beyond • Group-wide initiatives to improve efficiency and profitability in preparation • Medium-term growth targets confirmed th • 28 consecutive dividend increase proposed If no timeframe is specified, information refers to Q4/2020 2020 and 2019 according to IFRS 16 Growth Q4/20 Growth in constant currency Sales €9.3 billion 0% 5% EBIT1 €1,251 million -3% 2% Net income1,2 €494 million -2% 2% Growth FY/20 Growth in constant currency Sales €36.3 billion 2% 5% EBIT1 €4,612 million -2% 0% Net income1,2 €1,796 million -4% -3% 1 Before special items 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA For a detailed overview of special items please see the reconciliation tables on pages 20-22. Page 1/30 Fresenius SE & Co. KGaA, Investor Relations & Sustainability, 61346 Bad Homburg Stephan Sturm, CEO of Fresenius, said:” The pandemic year 2020 showed emphatically the importance of forward-thinking, effective and efficient healthcare. Fresenius is making a vital contribution here, in many different areas of medicine. This year, the pandemic will again present us with a number of challenges, making it even more important that we increase efficiency in order to improve our cost base.
[Show full text]
Einladung Zur Ordentlichen Hauptversammlung ISIN: DE0005785604// WKN: 578 560 ISIN: DE0005785620 // WKN: 578 562 ISIN: DE0005785638 // WKN: 578 563
Einladung zur ordentlichen Hauptversammlung ISIN: DE0005785604// WKN: 578 560 ISIN: DE0005785620 // WKN: 578 562 ISIN: DE0005785638 // WKN: 578 563 Wir laden hiermit unsere Aktionäre zu der am Mittwoch, dem 28. Mai 2003, um 10 Uhr im Marriott Hotel Frankfurt, Hamburger Allee 2 - 10, 60486 Frankfurt am Main, stattfindenden ordentlichen Hauptversammlung ein. Tagesordnung 1. Vorlage des festgestellten Jahresabschlusses der Fresenius AG und des Konzern- Abschlusses für das Geschäftsjahr 2002. Vorlage der Lageberichte für den Fresenius- Konzern und die Fresenius AG für 2002. Vorlage des Berichts des Aufsichtsrats. 2. Beschlussfassung über die Verwendung des Bilanzgewinns. Vorstand und Aufsichtsrat schlagen vor, den im Jahresabschluss für das Geschäftsjahr 2002 ausgewiesenen Bilanzgewinn von Euro 47.807.637,93 wie folgt zu verwenden: Zahlung einer Dividende von Euro 1,14 je Stammaktie auf Stück 20.484.842 dividendenberechtigte Stammaktien Euro 23.352.719,88 Zahlung einer Dividende von Euro 1,17 je Vorzugsaktie auf Stück 20.484.842 dividendenberechtigte Vorzugsaktien Euro 23.967.265,14 Die Dividende ist am 29. Mai 2003 zahlbar. Vortrag auf neue Rechnung Euro 487.652,91 Euro 47.807.637,93 1 3. Beschlussfassung über die Entlastung des Vorstands für das Geschäftsjahr 2002. Vorstand und Aufsichtsrat schlagen vor, Entlastung zu erteilen. 4. Beschlussfassung über die Entlastung des Aufsichtsrats für das Geschäftsjahr 2002. Vorstand und Aufsichtsrat schlagen vor, Entlastung zu erteilen. 5. Wahlen zum Aufsichtsrat. Die Amtszeit der bisherigen Aufsichtsratsmitglieder endet mit Ablauf der Haupt- versammlung vom 28. Mai 2003. Der Aufsichtsrat setzt sich gemäß §§ 96 Absatz 1 und 101 Absatz 1 Aktiengesetz und § 7 Absatz 1 Nummer 1 Mitbestimmungsgesetz aus sechs von der Hauptversammlung und sechs von den Arbeitnehmern zu wählenden Mitgliedern zusammen.
[Show full text]
IFRS 16 Adoption in Germany March 2019 63190
MARCH 2019 IFRS 16 ADOPTION IN GERMANY A Ranking of the Leasing Obligations of DAX Companies IFRS 16 - Adoption in Germany A Ranking of the Leasing Obligations of DAX Components MARCH 2019 BACKGROUND AND HISTORY OF IFRS 16 Starting on 1 January 2019, companies will begin to adopt the new IFRS 16 lease accounting standard published by the International Accounting Standards Board (IASB). As one of the biggest accounting changes in history, IFRS 16 will result in listed companies transferring almost €3 trillion worth of liabilities onto corporate balance sheets over the coming years. Historically, only finance leases – leases that have a similar structure to asset purchases – have been reported as assets and liabilities on corporate balance sheets. Other leases, called operating leases, were “off-balance sheet” and were accounted for using principles similar to service contracts. Following the major US accounting scandals of the early 2000s such as WorldCom, Enron, and Arthur Andersen, off-balance sheet liabilities became a major focal point for the regulatory agencies that govern the capital markets in various countries around the world. Regulators were concerned that without corporations reporting leases on balance sheets, investors and analysts did not have sufficient information to evaluate the financial position of a company or easily make comparisons between peers in the same industry. In an effort to provide greater transparency, the IASB, which defines standards for international financial reporting, introduced a new set of lease accounting standards. IFRS 16 was first published in January 2016 and will supersede the current lease accounting standard IAS 17. IFRS 16 eliminates the operating leases classification.
[Show full text]
Behaviour of Pesticides in Air, Soil and Water K a D E
DIE AKADEMIE FRESENIUS 8th AGRO Conference: fate, exposure and regulatory issues Behaviour of Pesticides in Air, Soil and Water k a d e A m us at www.akademie-fresenius.de Visit i e for m ore 21 to 22 June 2006 tha n 10 yea F rs Frankfurt-Mörfelden/ r e s Germany e n i u s Highlights: • Revision of Council 91/414/EEC • Thematic Strategy on Sustainable Use of Pesticides • Thematic Strategy for Soil Protection • River basin management strategies • Zonal approach to fate and exposure assessment • Role of lysimeter studies • Modelling the fate and behaviour of Speakers: pesticides David Arnold Cambridge Envrionmental Assessments • • Non-agricultural uses of herbicides Renate Becker-Arnold BASF • Csaba Szentes Plant • GIS assessments in FOCUS ground Protection and Soil Conservation Service • Anne-Cécile water Cotillon European Commission • Andrew Craven (formerly) • Probabilistic approaches to aquatic Pesticides Safety Directorate • Herman Fontier Federal exposure assessment Public Service Health, Food Chain Safety and Environment • Peter Heininger Federal Institute of Hydrology • John • GeoPERA – a new German approach Hollis National Soil Resources Institute • Chris Holmes • Surface water as drinking water – Waterborne Environmental • Andreas Huber DuPont de new FOCUS Group Nemours • Christopher Leake Bayer CropScience • Mark • National approaches, e.g. view from Montforts RIVM • Michael Neumann Federal Hungary, Spain, The Netherlands, Environmental Agency • Stephen Nortcliff University of France Reading • Brigitte Remy INRA • Carine Saison
[Show full text]
FTSE Publications
2 FTSE Russell Publications FTSE EDHEC-Risk Efficient 19 August 2021 Eurozone Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 1&1 AG 0.12 GERMANY Continental 0.79 GERMANY Henkel KG Pref 0.21 GERMANY A2A 0.25 ITALY Covestro AG 0.22 GERMANY Henkel Kgaa ORD 0.1 GERMANY Aalberts NV 0.31 NETHERLANDS Covivio 0.24 FRANCE Hera 0.19 ITALY ABN AMRO Bank NV 0.45 NETHERLANDS Credit Agricole 0.18 FRANCE Hermes International S.C.A. 0.86 FRANCE Acciona S.A. 0.33 SPAIN Cts Eventim 0.22 GERMANY Hochtief 0.15 GERMANY Accor 0.15 FRANCE Daimler AG 0.17 GERMANY Huhtamaki 0.2 FINLAND Ackermans & Van Haaren 0.66 BELGIUM Danone 0.64 FRANCE Iberdrola 0.1 SPAIN ACS Actividades Cons y Serv 0.13 SPAIN Dassault Aviation S.A. 0.14 FRANCE Icade 0.42 FRANCE Adidas 0.11 GERMANY Dassault Systemes 0.15 FRANCE Iliad 0.39 FRANCE Adyen 0.46 NETHERLANDS Delivery Hero SE 0.35 GERMANY IMCD NV 0.23 NETHERLANDS Aegon NV 0.18 NETHERLANDS Deutsche Bank 0.16 GERMANY Imerys 0.24 FRANCE Aena SME SA 0.23 SPAIN Deutsche Boerse 0.25 GERMANY Inditex 0.14 SPAIN Aeroports de Paris 0.28 FRANCE Deutsche Lufthansa AG 0.53 GERMANY Infineon Technologies AG 0.36 GERMANY Ageas 0.43 BELGIUM Deutsche Post 0.14 GERMANY ING Group CVA 0.18 NETHERLANDS Ahold Delhaize 0.36 NETHERLANDS Deutsche Telekom 0.12 GERMANY Inmobiliaria Colonial S.A.
[Show full text]
Press Release Corporate Communications
Matthias Link Press Release Corporate Communications Fresenius SE Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2872 F +49 6172 608-2294 [email protected] www.fresenius.com January 13, 2010 Fresenius Kabi and Bayer Schering Pharma extend collaboration regarding HESylation® Technology Fresenius Kabi Deutschland GmbH and Bayer Schering Pharma AG have extended their collaboration in the field of HESylation® Technology. The companies started their cooperation in May 2009 and now have entered into the next phase of development. The extension of the collaboration is combined with a further payment to Fresenius Kabi. Under the Research, Development and License Agreement, Fresenius Kabi has licensed its proprietary HESylation® Technology to Bayer Schering Pharma. This technology platform is based on hydroxyethyl starch (“HES”) and may allow the prolongation of the active half-life of proteins. Fresenius Kabi is responsible for supporting Bayer Schering Pharma with respect to implementing HESylation Technology and providing the appropriate HES derivative to Bayer Schering Pharma. Under the agreement, Bayer Schering Pharma oversees the development and commercialization. Fresenius Kabi will receive milestone payments as well as royalties on sales for licensing of the HESylation® Technology. HESylation® Technology HESylation® Technology allows a targeted modification of drugs and their characteristics by site-specific coupling to HES molecules. HES-coupling enables the modification of key pharmacological parameters such as absorption, metabolization, half-life, water solubility and safety. Page 1/3 Fresenius Kabi’s Business Unit HESylation® Technology is a focused team of experienced professionals. With access to customized HES species and dedicated fully equipped R&D and GMP facilities the support for biopharmaceutical product developments are fulfilled at highest standards.
[Show full text]
Ftseurofirst 80
2 FTSE Russell Publications 19 August 2021 FTSEurofirst 80 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) Adidas 1.77 GERMANY Enel 1.79 ITALY Nordea Bank Abp 0.98 FINLAND Adyen 1.75 NETHERLANDS Engie 0.56 FRANCE Orange 0.54 FRANCE Ahold Delhaize 0.73 NETHERLANDS Eni 0.76 ITALY Pernod Ricard 1.15 FRANCE Air Liquide 2.02 FRANCE EssilorLuxottica 1.35 FRANCE Prosus 1.05 NETHERLANDS Airbus 1.78 FRANCE Ferrari NV 0.62 ITALY Repsol 0.42 SPAIN Akzo Nobel 0.57 NETHERLANDS Fortum 0.3 FINLAND Royal DSM 0.77 NETHERLANDS Allianz SE 2.55 GERMANY Fresenius Medical Care 0.42 GERMANY RWE 0.57 GERMANY Amadeus IT Group SA 0.74 SPAIN Fresenius SE & Co KGaA 0.52 GERMANY Safran 1.2 FRANCE Anheuser-Busch InBev 1.5 BELGIUM Generali 0.64 ITALY Sampo Oyi 0.58 FINLAND ASML Holding 6.76 NETHERLANDS Heineken NV 0.72 NETHERLANDS Sanofi 2.83 FRANCE AXA 1.21 FRANCE Henkel KG Pref 0.46 GERMANY SAP 3.88 GERMANY Banco Bilbao Vizcaya Argentaria 1.02 SPAIN Hermes International S.C.A. 1.12 FRANCE Schneider Electric 2.07 FRANCE Banco Santander 1.62 SPAIN Iberdrola 1.74 SPAIN Siemens AG 2.96 GERMANY BASF 1.79 GERMANY Inditex 0.92 SPAIN Siemens Energy 0.28 GERMANY Bayer AG 1.48 GERMANY Infineon Technologies AG 1.3 GERMANY Societe Generale 0.57 FRANCE BMW 0.84 GERMANY ING Group CVA 1.28 NETHERLANDS St Gobain (Cie De) 0.78 FRANCE BNP Paribas 1.69 FRANCE Intesa Sanpaolo 1.14 ITALY Symrise AG 0.44 GERMANY Carrefour 0.28 FRANCE KBC Group 0.52 BELGIUM Telefonica
[Show full text]
Eurex® IOC Liquidity Indicator
Historical Data on Demand Product: Eurex® IOC Liquidity Indicator File Description Field Format Definition DATE Current business date Date (YYYY.MM.DD) Technical instrument-identifier, see SecurityID LONG refdata-file for reference Time of calculation of the statistic VARCHAR MDStatisticTime with nanosecond time precision (HH24:MI:SS.NS) (UTC) MDStatisticID INTEGER Unique statistics identifier MDStatisticName VARCHAR Acronym for statistics MDStatisticValue VARCHAR Calculated statistics value The Eurex IOC Liquidity Indicator is provided for the following most liquid options listed on the Eurex Exchanges T7 trading system: Product code Product Category Product Name OGBS Fixed Income Options Options on Euro-Schatz Futures ODAX Index Options DAX® Options EURO STOXX 50 Index Dividend OEXD Index Options Options OESX Index Options EURO STOXX 50® Index Options OESB Index Options EURO STOXX® Banks Options OKS2 Index Options KOSPI 200 OSMI Index Options SMI® Options OVS Volatility Index Options VSTOXX Options ADS DAX Equity Options Adidas ALV DAX Equity Options Allianz BAS DAX Equity Options BASF BAY DAX Equity Options Bayer BEI DAX Equity Options Beiersdorf BMW DAX Equity Options BMW Version 1.0 CBK DAX Equity Options Commerzbank CON DAX Equity Options Continental DAI DAX Equity Options Daimler DBK DAX Equity Options Deutsche Bank DB1 DAX Equity Options Deutsche Börse DPW DAX Equity Options Deutsche Post DTE DAX Equity Options Deutsche Telekom EOA DAX Equity Options E.ON FRE DAX Equity Options Fresenius FME DAX Equity Options Fresenius Medical
[Show full text]
Contract Specifications for Futures Contracts and Options Contracts at Eurex Germany and Eurex Zürich […..] Annex a in Rela
Contract Specifications for Futures Contracts and Eurex14e Options Contracts at Eurex Germany and Eurex June 8July 2, 2007 Zürich Page 1 […..] Annex A in relation to subsection 1.6 of the contract specifications: Futures on components of Dow Jones EURO STOXX 50® Index / Dow Jones STOXX 600® Index (EUR) Produkt- Country Contract Minimum ID Code Size Price Change […..] France Télécom FTEF FR 100 0.01 Groupe Danone BSNG FR 100 0.01 Groupe Danone BSNF FR 100 0.01 […..] Futures on other Dow Jones STOXX 600® Index Product- Country Contract Minimum Price Currency components ID Code Size Change** […..] ACS Actividades de Construcción y Servisos OCIF ES 50 0.01 EUR Actelion ATLG CH 50 0.01 CHF Actelion ATLF CH 10 0.01 CHF […..] Banca Carige BCAF IT 500 0.0005 EUR Banca Intesa IESG IT 1000 0.0005 EUR Banca Intesa IESF IT 1000 0.0005 EUR […..] BMW BMWF DE 100 0.01 EUR Böhler-Uddeholm UDHF AT 10 0.01 EUR Bourbon GBBF FR 50 0,01 EUR […..] Continental CONG DE 100 0.01 EUR Converium Holding CHRF CH 100 0.01 CHF Corio CL6F NL 50 0.01 EUR […..] DEPFA Bank DEPF DE 100 0.01 EUR Deutsche Börse DB1G DE 100 0.01 EUR Deutsche Börse DB1F DE 100 0.01 EUR […..] Fresenius* FREG DE 50 0.01 EUR Fresenius Medical Care FMEH DE 100 0.01 EUR Fresenius Medical Care FMEG DE 100 0.01 EUR […..] GEA Group G1AF DE 100 0.01 EUR Geberit GBRF CH 10 0.01 CHF Geberit GBRG CH 50 0.01 CHF […..] Hannover Rückversicherung HNRF DE 100 0.01 EUR Contract Specifications for Futures Contracts and Eurex14e Options Contracts at Eurex Germany and Eurex June 8July 2, 2007 Zürich Page 2 Futures on other Dow Jones STOXX 600® Index Product- Country Contract Minimum Price Currency components ID Code Size Change** Hanson HNSF GB 1000 0.01 GBP HBOS HBOF GB 1000 0.01 GBP […..] Hellenic Telecommunications Organization OTEF GR 100 0.01 EUR Henkel Vz.
[Show full text]